PureTech Health (NASDAQ:PRTC) Now Covered by Leerink Partners

Leerink Partners started coverage on shares of PureTech Health (NASDAQ:PRTC) in a research note published on Monday, MarketBeat reports. The brokerage issued an outperform rating and a $45.00 price target on the stock.

PureTech Health Stock Up 0.5 %

PRTC opened at $19.89 on Monday. PureTech Health has a fifty-two week low of $17.08 and a fifty-two week high of $34.00. The company has a fifty day moving average of $22.26 and a two-hundred day moving average of $25.68.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in PureTech Health stock. Birch Hill Investment Advisors LLC acquired a new stake in PureTech Health plc (NASDAQ:PRTC) in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund acquired 302,000 shares of the company’s stock, valued at approximately $7,550,000. Birch Hill Investment Advisors LLC owned approximately 1.26% of PureTech Health as of its most recent filing with the Securities and Exchange Commission (SEC). 0.04% of the stock is owned by institutional investors and hedge funds.

PureTech Health Company Profile

PureTech Health plc, engages in the development and commercialization of biotechnology and pharmaceutical solutions in the United States. The company is developing LYT-100, which is under Phase 2 stage, to treat idiopathic pulmonary fibrosis (IPF); and LYT-200, a IgG4 monoclonal antibody, currently under Phase 1/2 stage, targeting galectin-9 for treating solid tumors and hematological malignancies.